Imunisasi

01Regulatory Framework and Rationale

The legal backbone of immunization in Indonesia rests on UU No. 17 Tahun 2023 (the Health Law), which replaced the older UU 36/2009 and mandates that immunization is both a right of every child and a public health obligation. Permenkes No. 2/2025 on Reproductive Health also explicitly guarantees every child the right to receive complete basic immunization from the government, with sanctions for individuals or institutions found to obstruct vaccination.

The operational regulation is Permenkes No. 12/2017, which replaced Permenkes 42/2013 and governs the entire immunization ecosystem: types of immunization, program and elective immunization delivery, KIPI surveillance, research and development, community participation, and recording/reporting systems. Before administering any program immunization, healthcare workers must explain the vaccine type, its benefits, consequences of not vaccinating, possible KIPI (adverse events following immunization), and the next scheduled dose. Article 9 mandates complete basic immunization as a school entry requirement for kindergarten and elementary school, with exemption only for documented medical contraindications.

The immunization schedule itself is governed by a separate ministerial decree. The current version is KMK No. HK.01.07/MENKES/1098/2024, effective July 1, 2024, which was then amended by KMK No. HK.01.07/MENKES/35/2025 (effective January 21, 2025). The 2025 amendment adjusted the HPV immunization schedule from two doses to one dose, aligning with the WHO SAGE recommendation and Indonesia's national commitment to cervical cancer elimination by 2030.

For the exam, there is also a parallel recommendation from the IDAI (Ikatan Dokter Anak Indonesia), published in the Pedoman Imunisasi Edisi 7 Tahun 2024. This 7th edition textbook addresses the latest developments including the IDAI 2024 immunization schedule, newer vaccines, catch-up immunization, simultaneous injection protocols, and KIPI reporting. The IDAI schedule includes additional "pilihan" (elective) vaccines not covered by the government program, such as Influenza, Hepatitis A, Varicella, Typhoid, and Dengue. A vignette may test whether a student can distinguish between a program vaccine (free, mandatory) and a pilihan vaccine (paid, recommended but not mandated by Kemenkes).

02Imunisasi Rutin Schedule

This is the highest-yield section for exam purposes. The schedule below is drawn directly from KMK 1098/2024 as amended by KMK 35/2025.

Infant Immunization (0-11 months)

Hepatitis B birth dose must be given within 24 hours of life. The reasoning is that vertical transmission from an HBsAg-positive mother occurs perinatally. The birth dose provides immediate passive-active immunoprophylaxis. An exam vignette describing a newborn whose mother is HBsAg(+) will expect you to answer "HBIg + HB-0 within 12 hours" as the next best step. When the mother's status is unknown, HB-0 alone is still given within 24 hours.

BCG is the only vaccine given intradermally (intrakutan) at 0.05 mL. Every other injectable vaccine is given IM or SC. BCG is given at 1 month and must be completed before the child turns 1 year. There is no catch-up for BCG beyond 11 months in the government program. If a vignette mentions a child who never received BCG and is now 2 years old, the answer is that BCG catch-up is no longer part of the routine program schedule.

Polio vaccine strategy uses a sequential bOPV + IPV schedule. The oral bivalent OPV (bOPV) is given at birth/1 month, 2, 3, and 4 months (4 doses total). IPV is given at 4 months and 9 months (2 doses). This dual approach ensures both mucosal immunity (from OPV, which induces intestinal IgA) and robust systemic humoral immunity (from IPV). The distinction between OPV and IPV is commonly tested. OPV is a live-attenuated vaccine and carries a rare risk of vaccine-associated paralytic poliomyelitis (VAPP) or circulating vaccine-derived poliovirus (cVDPV). IPV is an inactivated vaccine with no such risk. Indonesia experienced cVDPV2 outbreaks in recent years, which drove the introduction of nOPV2 (novel OPV type 2) in outbreak response settings.

DPT-HB-Hib is a pentavalent combination vaccine covering five antigens in a single injection. It is given in a 3-dose primary series at 2, 3, and 4 months. Note the interval: Indonesia uses a monthly interval (4 weeks) for the primary series, which differs from the 2-4-6 month schedule used in some other countries. A booster (4th dose) is given at 18 months (see Baduta schedule below).

PCV is given at 2 and 3 months (primary series), with a booster at 12 months. This 2+1 schedule is key for the exam. PCV protects against invasive pneumococcal disease (IPD), including pneumococcal pneumonia, meningitis, and bacteremia. PCV was introduced into Indonesia's national program relatively recently.

Rotavirus vaccine is given as 3 doses at 2, 3, and 4 months. The pentavalent formulation (RotaTeq-type) requires all 3 doses to be completed before age 32 weeks (approximately 7 months). If the first dose is not given before 15 weeks, the series should not be initiated due to a theoretical increased risk of intussusception in older infants. This upper age limit is a common exam trap.

MR (Campak-Rubella) at 9 months is given subcutaneously, not IM. This is a common detail tested in practical exams. The second dose follows at 18 months. A third opportunity is given in Grade 1 (BIAS).

JE is only given in endemic areas. In exam context, the student must know that JE is not part of the nationwide schedule. If the vignette does not mention that the child lives in an endemic region (e.g., Bali, parts of NTB, NTT, Papua), JE is not applicable.

Toddler / Baduta Immunization (12-23 months)

The 18-month visit is a high-yield "bundled" visit. Two vaccines are given simultaneously: DPT-HB-Hib booster and MR-2. Simultaneous injection at different anatomic sites (e.g., left thigh for one, right thigh for the other) is permitted and encouraged under both Kemenkes and IDAI guidelines.

School-Age Immunization (BIAS)

BIAS (Bulan Imunisasi Anak Sekolah) is the school-based immunization month conducted by puskesmas teams in coordination with schools. The key update per KMK 35/2025: Starting in 2025, HPV immunization was changed from 2 doses to 1 dose, following the WHO SAGE recommendation and Indonesia's national plan for cervical cancer elimination by 2030.

Note the difference between DT (capital T, full-dose diphtheria + tetanus, given in Grade 1) and Td (lowercase d, reduced-dose diphtheria + tetanus, given in Grade 2 and Grade 5). The "big D" vs "small d" distinction reflects diphtheria toxoid concentration. After age 7, the reduced diphtheria component is used because older children and adults are more prone to adverse reactions with the full pediatric dose. This is a frequently tested concept.

Adolescent, Adult, and Elderly Immunization

The government program for these groups currently covers:

COVID-19 vaccination for immunocompromised adolescents (2-3 doses), adults with comorbidities (1 dose or booster at 12 months post-last-dose), healthcare workers (1 dose or booster at 12 months), pregnant women (1 dose per pregnancy when vaccine is available), and the elderly (1 dose, with boosters at 6 or 12 months depending on comorbidity status).

Tetanus toxoid (Td) for women of reproductive age (WUS) follows a 5-dose lifetime schedule (T1 through T5) with minimum intervals: T2 at 1 month after T1, T3 at 6 months after T2, T4 at 12 months after T3, T5 at 12 months after T4. Status is screened at every antenatal care visit.

Hepatitis B for healthcare workers is given as 3 doses (0-1-6 month schedule) only after screening confirms both HBsAg(-) and anti-HBs(-).

03Catch-Up Immunization (Imunisasi Kejar)

This concept is commonly tested. If a child has missed doses and presents late, the principle is: never restart a series; continue from where the child left off. The catch-up rules per KMK 1098/2024 and its 2025 amendment are summarized below.

The most testable catch-up rules include:

The PCV catch-up is age-dependent. A child presenting at 12-24 months who has never received PCV gets 2 doses (8 weeks apart). A child older than 24 months but under 5 years gets only 1 dose. After age 5, PCV is no longer in the routine program.

Rotavirus has the strictest upper age limit. All 3 doses must be completed before 7 months of age with a minimum 4-week interval. If a child presents at 8 months having never received rotavirus vaccine, the opportunity is lost.

The HPV catch-up per KMK 35/2025 is now a single dose for girls in Grade 6 or up to age 15 (Grade 9 / SMP) who have never been vaccinated. This is a departure from the previous 2-dose schedule.

04Supplementary Immunization & Traveler Immunization

Supplementary immunization (imunisasi tambahan) is distinct from routine immunization. It is given to targeted groups who are at highest risk of contracting a vaccine-preventable disease, based on epidemiologic assessment, during a defined time period.

The activities classified under supplementary immunization include Backlog Fighting, Crash Program, PIN (Pekan Imunisasi Nasional), Sub-PIN, Catch-Up Campaign Campak, and ORI (Outbreak Response Immunization).

The key unifying principle is that supplementary immunization is given regardless of prior vaccination status to rapidly build population-level immunity.

Summary Table

Backlog Fighting

Backlog fighting is an active effort to complete basic immunization (imunisasi dasar) in children aged 1-3 years. The priority targets are villages or kelurahan that have failed to achieve UCI (Universal Child Immunization) status for two consecutive years.

UCI means that at least 80% of infants in a village have received complete basic immunization. When a village repeatedly falls below this threshold, it signals a pocket of susceptible children that could fuel an outbreak. Backlog fighting is therefore a proactive, localized, case-finding approach. Health workers go door-to-door or conduct special Posyandu sessions to identify and vaccinate children whose immunization is incomplete.

The difference between backlog fighting and routine catch-up immunization (imunisasi kejar) is the programmatic trigger. Routine catch-up happens when any individual child is identified as behind schedule during a regular visit. Backlog fighting is a systematic, area-based campaign triggered by population-level coverage data. For the exam, if a vignette describes a puskesmas in a remote area with low UCI rates for two years running, and asks "what is the appropriate immunization strategy?", the answer is backlog fighting.

Crash Program

Crash program is a supplementary immunization activity aimed at areas requiring rapid intervention to prevent an outbreak (KLB). The criteria for selecting crash program locations include: (1) high infant mortality rate and high incidence of PD3I, (2) shortage of healthcare workers, facilities, or funding, and (3) villages that have failed to reach the UCI target for 3 consecutive years.

The critical distinction from backlog fighting is the duration and urgency threshold. Backlog fighting targets areas failing UCI for 2 years. Crash program targets areas failing for 3 years, with the additional compounding factors of high PD3I burden and resource constraints, meaning the situation has deteriorated further. Crash program also differs in that it gives the vaccine to all children in the target group without consideration of prior immunization status, whereas backlog fighting aims to complete missing individual doses.

Think of it this way: backlog fighting is a targeted "fill-the-gaps" strategy. Crash program is a "blanket coverage" strategy where the epidemiologic risk is high enough that checking individual status is not practical or not sufficient.

Catch-Up Campaign Campak (and BIAN)

The Catch-Up Campaign for Measles-Rubella is the largest and most recent example of supplementary immunization in Indonesia. The most notable execution was the BIAN (Bulan Imunisasi Anak Nasional) in 2022.

The BIAN campaign aimed to vaccinate approximately 36.5 million children through a single dose of measles-rubella immunization for children under 15 years of age across all provinces except Bali and Yogyakarta (where coverage already met national targets), and to provide catch-up routine immunization for toddlers in all 34 provinces.

BIAN consisted of two integrated activities:

• Supplementary immunization in the form of one dose of MR given en masse regardless of prior immunization status

• Catch-up immunization to complete OPV, IPV, and DPT-HB-Hib doses for children aged 12-59 months who had missed scheduled doses.

The campaign was conducted in two phases. Phase 1 began in May 2022 for all provinces outside Java and Bali. Phase 2 began in August 2022 for provinces in Java and Bali. The campaign reached 26.5 million children with measles and rubella vaccines, 1.3 million with polio vaccines, and 2 million with DTP-HB-Hib vaccines.

The rationale for BIAN was the steep decline in routine immunization coverage during the COVID-19 pandemic. Children who received their first measles-rubella vaccination dropped from 95% in 2019 to 87% in 2021, and the proportion of "zero dose" children (those who received no DPT dose at all) rose from 10% in 2019 to 26% during the same period. This created a large cohort of unprotected children at risk of PD3I outbreaks.

For exam purposes, the Catch-Up Campaign/BIAN is an example of a nationally coordinated supplementary immunization activity with two components: a non-selective supplementary dose (MR to all, regardless of status) and a selective catch-up component (completing missed routine doses based on individual status). Know that these two components serve different immunologic purposes. The non-selective MR dose boosts population immunity even in previously vaccinated children, closing gaps left by primary vaccine failure. The selective catch-up addresses individual susceptibility.

Pekan Imunisasi Nasional (PIN)

PIN (Pekan Imunisasi Nasional) is an immunization activity conducted simultaneously across the entire country within a short time period.

PIN has historically been used for polio eradication. PIN Polio involves administering supplementary oral polio vaccine to all children under 5 regardless of prior polio vaccination status, with the goal of reducing the risk of poliovirus transmission, ensuring population-level immunity is sufficiently high, and providing optimal and equitable protection against polio.

In 2024, the Ministry of Health conducted PIN Polio in two rounds across 33 provinces, in response to confirmed polio cases in several regions of Indonesia. This was triggered by the detection of acute flaccid paralysis (AFP) cases confirmed as poliovirus type 2 in regions such as Kabupaten Nduga (Papua).

The defining features of PIN that distinguish it from other supplementary activities are:

Scope: nationwide, all provinces simultaneously. Target: all balita (under 5), including children who are visiting or transiting through the area. Vaccine: given regardless of prior vaccination status. Duration: conducted within a short, defined period (typically one week per round, with at least one month between rounds).

PIN is the "nuclear option" of supplementary immunization. It is deployed when the threat level is national (e.g., poliovirus circulation in multiple provinces, or Indonesia's polio-free status is at risk).

Sub-PIN (Sub Pekan Imunisasi Nasional)

Sub-PIN is a geographically limited version of PIN, targeting selected provinces, districts, or cities rather than the entire country.

Sub-PIN Polio conducted in January-February 2024 was a response to confirmed cases of acute flaccid paralysis in Pamekasan and Sampang (East Java) and Klaten (Central Java), using two rounds of nOPV2 (novel Oral Polio Vaccine type 2) given as two drops with a minimum one-month interval between rounds. The target population was children aged 0-7 years, regardless of prior immunization status.

The key difference between PIN and Sub-PIN is geographic scope. PIN covers the entire nation. Sub-PIN covers only the provinces or districts epidemiologically linked to the confirmed cases. This distinction is commonly tested. A vignette describing a polio case confirmed in one province, with Sub-PIN conducted in surrounding provinces, tests whether the student understands the tiered response: Sub-PIN for regional containment versus PIN when the threat is national.

Sub-PIN also uses the newest available vaccine formulation for the target pathogen. In the 2024 Sub-PIN for cVDPV2, the vaccine used was nOPV2 (novel OPV type 2), a genetically stabilized version of OPV2 designed to reduce the risk of vaccine-derived poliovirus emergence compared to the original Sabin OPV2. This is a high-yield detail: nOPV2 was granted Emergency Use Listing by WHO and has been deployed in several countries experiencing cVDPV2 outbreaks.

ORI (Outbreak Response Immunization)

ORI is immunization conducted in direct response to a confirmed KLB (Kejadian Luar Biasa / outbreak), with the goal of rapidly achieving individual and community immunity to break the chain of transmission of a vaccine-preventable disease.

ORI differs from Crash Program in timing and trigger:

ORI is typically deployed for diseases like diphtheria, measles, and polio. The technical guidelines for each ORI are issued by the Dirjen P2P (Directorate General of Disease Prevention and Control) on a case-by-case basis, specifying the target age group, vaccine type, number of rounds, and geographic scope.

For the exam, when a vignette describes a confirmed diphtheria outbreak in a district and asks for the appropriate public health response, the answer includes: (1) case management (antitoxin + antibiotics for the index case), (2) chemoprophylaxis for close contacts, and (3) ORI with diphtheria-containing vaccine (DPT-HB-Hib or Td, depending on age) in the affected and surrounding areas.

Traveler Immunization (Imunisasi Khusus)

Traveler immunization in the government program is distinct from supplementary immunization. Special immunization (imunisasi khusus) is conducted to protect the community against certain diseases in certain situations, including preparation for Hajj/Umrah pilgrimage, travel to endemic countries, and outbreak conditions.

The only traveler vaccine currently in the government program is the meningococcal meningitis vaccine for Hajj pilgrims. The polysaccharide formulation (for individuals older than 2 years) provides 3 years of protection, while the conjugate formulation (for individuals older than 9 months) provides 5 years of protection. This vaccine is administered at designated Kantor Kesehatan Pelabuhan (KKP) or other authorized vaccination centers, and an International Certificate of Vaccination (ICV) is issued per Permenkes 13/2016.

A classic exam trap is confusing the meningococcal vaccine (required for Hajj, given to travelers) with the Hib vaccine (routine infant immunization, protects against H. influenzae type b meningitis). These target completely different organisms. The Hajj-required vaccine targets Neisseria meningitidis, not Haemophilus influenzae.

05Adverse Events Following Immunization (KIPI)

KIPI (Kejadian Ikutan Pasca Imunisasi) is the Indonesian equivalent of AEFI (Adverse Events Following Immunization). Every healthcare facility conducting immunization must routinely report KIPI data including immunization coverage, vaccine stock and usage, ADS (Auto-Disable Syringe), safety box, temperature monitoring, cold chain equipment condition, and any KIPI or suspected KIPI cases.

The KIPI classification system follows the WHO Brighton Collaboration framework:

Vaccine product-related reaction: an event caused by the vaccine itself (e.g., BCG lymphadenitis, OPV-associated VAPP). Vaccine quality defect-related: a problem with the vaccine formulation, cold chain breach, or manufacturing error. Immunization error-related: incorrect dose, wrong route, wrong injection site, non-sterile technique, expired vaccine. Immunization anxiety-related: vasovagal syncope, hyperventilation. Coincidental: an event that would have occurred regardless of immunization.

For the exam, the most commonly tested KIPI scenarios include:

The child who develops a BCG abscess or ipsilateral axillary lymphadenopathy weeks after BCG vaccination. This is a known vaccine product-related reaction and does not contraindicate future immunization with other vaccines.

The infant who develops intussusception within 7 days of rotavirus vaccine. This is a recognized rare adverse event, and the risk is highest after the first dose, which is why there is a strict upper age limit for initiation.

A high-pitched cry lasting >3 hours or a temperature >40.5 C within 48 hours after DPT-HB-Hib. These are recognized reactions. However, a hypotonic-hyporesponsive episode (HHE) or seizure within 3 days of DPT represents a more serious event requiring individual risk-benefit assessment before subsequent doses.

True anaphylaxis to any vaccine component is a contraindication to further doses of that vaccine or any vaccine containing the same component.

06Cold Chain and Vaccine Storage

This is a high-yield administrative and practical topic often tested in the exam, particularly in the public health / community medicine section.

The critical concept is the distinction between freeze-sensitive vaccines and heat-sensitive vaccines. Vaccines containing aluminum adjuvant (all inactivated/subunit vaccines such as DPT-HB-Hib, Hepatitis B, PCV, IPV, Td, HPV) are permanently damaged by freezing. Once frozen, the aluminum salt aggregates, reducing immunogenicity and increasing the risk of local reactions. These vaccines must pass a shake test if freezing is suspected: after vigorous shaking, if the vaccine sediments faster than a known-frozen control, it must be discarded.

The VVM (Vaccine Vial Monitor) is a thermochromic label on the vaccine vial that changes color with cumulative heat exposure. The VVM has 4 stages: if the inner square is lighter than the outer circle, the vaccine is usable. If the inner square matches or is darker than the outer circle, the vaccine has been exposed to excessive heat and must be discarded. This concept is commonly tested using images.

At puskesmas level, vaccines are stored in a vaccine refrigerator (not a domestic refrigerator). The temperature must be monitored twice daily (morning and afternoon) and logged. The cold chain extends from Biofarma (national manufacturer/distributor) through provincial and district cold rooms, down to puskesmas refrigerators, and finally into vaccine carriers used during Posyandu or outreach sessions.

07Program vs Elective (Pilihan) Vaccines

This distinction is a common exam trap. The table below clarifies which vaccines are program (government-funded, mandatory) and which are pilihan (recommended by IDAI but paid for by the family).

The test-writer loves this distinction. A vignette describing a family at a puskesmas will only have program vaccines available free of charge. If asked "which vaccine should this child receive at age 12 months at the puskesmas?", the answer is PCV-3 (booster). Influenza or Hepatitis A would not be the answer because these are not part of the program.

Conversely, a vignette set in a private pediatric practice may test knowledge of the full IDAI schedule, including elective vaccines.

08Differential Diagnosis and Distractors

In this context, "distractors" refer to exam traps where the test-writer tries to confuse students between related immunization concepts.

09Traps and High-Yield Pearls

The most common way students lose points on immunization questions is by conflating the Kemenkes program schedule with the IDAI recommended schedule. The exam may present a puskesmas-based vignette and include an IDAI-only vaccine (like Hepatitis A or Varicella) as a distractor answer choice. Always identify the setting first. Public health / puskesmas setting = program vaccines only.

A second frequent trap involves vaccine route of administration. BCG is intradermal (0.05 mL), MR is subcutaneous, and nearly everything else is intramuscular. A question asking "which vaccine is given subcutaneously?" with choices of DPT-HB-Hib, BCG, MR, and IPV has the answer MR. BCG is intradermal, not subcutaneous.

Third, the HPV dose update is a hot topic. Any question referencing the 2025 schedule that asks for HPV dosing should be answered as 1 dose, Grade 5 girls. The catch-up extends to Grade 6 and up to age 15 (Grade 9) for girls who have never received the vaccine. The two-dose schedule is now outdated per national policy.

Fourth, understand that KIPI reporting is mandatory for all healthcare facilities, and the framework distinguishes vaccine product-related, quality-related, immunization error-related, anxiety-related, and coincidental events. A vignette describing a child who develops fever and convulsion 2 days after DPT-HB-Hib is testing whether you recognize this as a possible vaccine product-related adverse event (DPT is a known cause of febrile seizures) versus an immunization error or a coincidental febrile illness.

Finally, the cold chain question is a staple of the public health section. Know the shake test, VVM stages, the difference between freeze-sensitive and heat-sensitive vaccines, and the 2-8 C storage requirement. A question showing a VVM image where the inner square has darkened to match the outer ring means the vaccine is no longer usable, regardless of its expiration date.